Cancer feature: cnaPANCAN230

AKIRIN2 ANKRD6 ASCC3 BACH2 BCKDHB C6orf163 C6orf164 C6orf165 C6ORF165 CCNC CGA CNR1 COQ3 CYB5R4 DOPEY1 ELOVL4 EPHA7 FAM46A FAXC FBXL4 FHL5 FUT9 GABRR1 GABRR2 GJA10 GJB7 GPR63 GRIK2 HMGN3 HTR1B HTR1E IBTK IRAK1BP1 KIAA1009 KLHL32 LCA5 LYRM2 MANEA MAP3K7 MCHR2 MDN1 ME1 MEI4 MMS22L MRAP2 NDUFAF4 NT5E ORC3 PGM3 PHIP PM20D2 PNISR PNRC1 POU3F2 PRDM13 PRSS35 RARS2 RIPPLY2 RNGTT RP1-102H19.8 RP11-321N4.5 RRAGD RWDD2A SH3BGRL2 SIM1 SLC35A1 SMIM8 SNAP91 SNX14 SPACA1 SRSF12 SYNCRIP TBX18 TPBG TTK UBE2J1 UBE3D UFL1 USP45 ZNF292

Known Driver Genes: None

Copy number alternation: loss

Wee1 Inhibitor

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer